Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The «Price of Progress»

Infect Dis Clin North Am. 2020 Sep 30:S0891-5520(20)30030-1. doi: 10.1016/j.idc.2020.05.001. Online ahead of print.

ABSTRACT

Significant advances were made in antibiotic development during the past 5 years. Novel agents were added to the arsenal that target critical priority pathogens, including multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales. Of these, 4 novel β-lactam-β-lactamase inhibitor combinations (ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-cilastatin-relebactam) reached clinical approval in the United States. With these additions comes a significant responsibility to reduce the possibility of emergence of resistance. Reports in the rise of resistance toward ceftolozane-tazobactam and ceftazidime-avibactam are alarming. Clinicians and scientists must make every attempt to reverse or halt these setbacks.

PMID:33011051 | DOI:10.1016/j.idc.2020.05.001